Scholars Central

Conference abstractPublished 26 Oct 2015

Biosimilar Companies and Market Development Worldwide

Authors: Lisa Mueller

Michael Best & Friedrich LLP, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Biosimilars are highly-similar versions of biological drugs (biologics) approved for the treatment of a variety of disorders and diseases. Originator biologics are the most expensive drugs in the pharmaceutical industry and many cost nearly $100,000 per patient per year. As a result, biologics impose a heavy financial burden on patients and healthcare systems. While patent protection for several biologics has already expired, several other biologics are expected to lose patent protection between now and 2020. This impending patent cliff has given many biotechnology companies the opportunity to develop and market biosimilars with a cost benefit of about 20% to 30%. In order to gain a slice of the $190 billion worth of biologic’s market, many biotechnology companies have ventured into the biosimilar sector. This session will examine the key players that have ventured into this sector as well as the size and development of the market worldwide.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • BylineArticles whose byline prints “Lisa Mueller”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels